Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children.

Background: Sleep disorders are often underreported to physicians by patients with allergies. This study aimed to characterize the sleep disorders associated with respiratory allergy to house dust mites (HDM) at the time of initiation of sublingual allergen immunotherapy (SLIT) in routine clinical practice.

Methods: This prospective, cross-sectional, observational study was conducted between November 2014 and March 2015 at 189 French trial sites and included 1750 participants suffering from HDM allergy who were initiating SLIT.

Chronic venous diseases: roles of various pathophysiological factors.

Disturbances in haemodynamic, biochemical and enzymatic factors have been observed in chronic venous diseases (CVD). These changes lead to the development of varices, telangiectasies and skin disorders. They affect vessels, blood, skin tissues and cells.

Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated unsomniacs.

The effects of zolpidem 10 mg, flunitrazepam 1 mg, and placebo, administrated at bedtime, were studied in 12 healthy male insomniac patients. The assessments included polygraphic sleep recordings during the night and a battery of cognitive tests (sign crossing test, dichotic listening test, digit span test, visual recognition test and free recall test during four times during the following day. Compared with placebo, both active drugs improved sleep parameters.

Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD.

Study Objective: To assess the effects of repeated 10-mg oral doses of zolpidem on diurnal and nocturnal respiratory function, as well as on diurnal vigilance and physical performance in COPD patients with disordered sleep.

Design: Prospective single-blind placebo-controlled clinical study.

Setting: Outpatients of a respiratory medicine department.

Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.

In a parallel-group, placebo-controlled, polysomnographic study with randomization, the possible occurrence of rebound insomnia was evaluated in 24 patients suffering from moderate to severe chronic insomnia and receiving either triazolam 0.5 mg, zolpidem 10 mg, or placebo. Treatment duration was 27 nights, followed by three placebo-controlled withdrawal nights.